Spyre Therapeutics, Inc.
SYRE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -100% | -62% | -87.6% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | 100% | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -14,401.8% | -3,555.9% | -341.9% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -38,238.1% | -3,598.8% | -351.1% |
| EPS Diluted | -3.18 | -46.15 | -24.86 | -25.02 |
| % Growth | 93.1% | -85.6% | 0.6% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |